GLP-1 Agonists: A New Era for Cardiometabolic Treatment
Executive Summary Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of incretin mimetics originally developed for the management of type 2 diabetes, are now at the forefront of a paradigm shift in the treatment of cardiometabolic disease. Their potent effects on glycemic control are complemented by significant weight reduction and proven cardiovascular benefits. This has led…